About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

 

 

Spotlight

Sanofi and MannKind  Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin 
More >

News & Events

   
Oct 27, 2014 MannKind Corporation to Hold 2014 Third Quarter Financial Results Conference Call... More >
Sep 29, 2014 MannKind Announces Receipt of $150 Million Licensing Upfront Payment More >
Sep 25, 2014 MannKind Announces Closing of Global Licensing Agreement With Sanofi More >